| Product NDC: | 55253-070 |
| Proprietary Name: | fentanyl citrate |
| Non Proprietary Name: | fentanyl citrate |
| Active Ingredient(s): | 200 ug/1 & nbsp; fentanyl citrate |
| Administration Route(s): | TRANSMUCOSAL |
| Dosage Form(s): | LOZENGE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 55253-070 |
| Labeler Name: | CIMA Laboratories, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020747 |
| Marketing Category: | NDA AUTHORIZED GENERIC |
| Start Marketing Date: | 20060906 |
| Package NDC: | 55253-070-30 |
| Package Description: | 10 BLISTER PACK in 1 CARTON (55253-070-30) > 3 LOZENGE in 1 BLISTER PACK (55253-070-01) |
| NDC Code | 55253-070-30 |
| Proprietary Name | fentanyl citrate |
| Package Description | 10 BLISTER PACK in 1 CARTON (55253-070-30) > 3 LOZENGE in 1 BLISTER PACK (55253-070-01) |
| Product NDC | 55253-070 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | fentanyl citrate |
| Dosage Form Name | LOZENGE |
| Route Name | TRANSMUCOSAL |
| Start Marketing Date | 20060906 |
| Marketing Category Name | NDA AUTHORIZED GENERIC |
| Labeler Name | CIMA Laboratories, Inc. |
| Substance Name | FENTANYL CITRATE |
| Strength Number | 200 |
| Strength Unit | ug/1 |
| Pharmaceutical Classes | Full Opioid Agonists [MoA],Opioid Agonist [EPC] |